Horizon Diagnostics Blog

Combatting the challenges of liquid biopsy with cfDNA synthetic plasma Reference Standards

Aug 10, 2018 3:46:08 PM No Comments

Liquid biopsy holds many advantages over solid tumor testing of cancer patients. It is less invasive for the patient, avoiding the need for surgical biopsy, and has improved levels of sensitivity to detect low frequency somatic driver mutations.   

The industry is pushing for liquid biopsy to become the go-to method for the collection of clinical DNA samples for oncology genotyping. This could be at the point of diagnosis - for routine monitoring during treatment to detect the appearance of resistance mutations, which may indicate a change of therapy is required. Alternatively, liquid biopsy could be used for future preventative cancer screening of the general population before disease symptoms appear - to facilitate earlier diagnosis and better treatment outcomes.

Read More Oncology Panels, NGS, cfDNA, Reference Standards, Oncology

The growing impact of liquid biopsies on precision medicine

Oct 11, 2017 10:30:20 AM No Comments

 Liquid biopsies are becoming increasingly popular in cancer research. We take a look at their potential impact in the clinic and how current technologies can help us keep pushing the boundaries of precision medicine. 

Read More NGS, cfDNA, Reference Standards

SHERLOCK: The case of the disruptive diagnostic

May 10, 2017 2:07:05 PM No Comments

“SHERLOCK is exciting because it represents a sensitive approach to detect mutations, much like PCR, but it does not require a thermocycler and could work as a bedside test.” - Dr Tilmann Buerckstuemmer, Global Head of Innovation at Horizon Discovery

Read More CRISPR, cfDNA

Subscribe to Email Updates

RECENT POSTS